- $495.69m
- $403.02m
Brief: First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform
Brief: IND Amendment Clearance Obtained For Clinical Manufacturing Of Rese-Cel From Cabaletta Bio Using Cellares' Automated Platforms
Cabaletta Bio reports smaller-than-expected Q3 loss
U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity
Cabaletta surges after early data on cell therapy for autoimmune skin disease
Brief: Cabaletta Bio Inc Reports New Data From RESET-PV Trial
Cabaletta Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Cabaletta Bio Inc Files For Mixed Shelf Offering Of Up To $240 Million- SEC Filing
Cabaletta Bio Inc expected to post a loss of 65 cents a share - Earnings Preview
Cabaletta Bio Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Cabaletta Bio Announces 2027 Rese-Cel BLA Submission Anticipated In Myositis Following Recent FDA Alignment On Registrational Cohorts
Cabaletta Bio Inc expected to post a loss of 64 cents a share - Earnings Preview
Cabaletta Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Cabaletta Bio Inc expected to post a loss of 64 cents a share - Earnings Preview
Brief: Cabaletta Bio Announces Updated Clinical Data With Rese-Cel At February Scientific Meetings
Brief: Cabaletta Bio Outlines Strategic Priorities And Anticipated Key Milestones For 2025
Cabaletta Bio Inc reports results for the quarter - Earnings Summary
Cabaletta Bio Inc expected to post a loss of 60 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Duolingo, Nova, Universal Health Services